Oventus Medical Ltd (ASX:OVN) announces its Appendix 4C Report for the three-month period ending 30 June 2018 (Q4 FY2018) and is pleased to provide a review of progress made during the quarter.
Nanollose Ltd (ASX:NC6) provides the Company Update Presentation.
Queensland Bauxite Limited (ASX:QBL) is delighted to announce that Medcan Australia, has now been issued with both an Import & Export Licence under the ODC.
As reported in the announcement released by Queensland Bauxite Limited (ASX:QBL) on 13th July 2018, the Notice of Meeting for the recompliance transactions is still being drafted and is yet to be reviewed by the ASX. The following table is the timeline to which the Company is currently working towards for the completion of the transactions and the recompliance requirements.
Since a Q&A on the ASX forum was announced (2 July '18), Queensland Bauxite Limited (ASX:QBL) has received many questions mainly by shareholders who were daunted by the 131 page announcement and are eager to understand further the Company's current strategy.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the United States Patent Office has issued a notice of allowance for issuance of a patent covering the composition and use of Progenza.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced it was on track to complete its clinical collaboration with a Japanese partner for Progenza in Japan in the near-term. The company had disclosed that it anticipated completing the collaboration before the end of 30 June but discussions have taken longer than originally anticipated.
